Skip to Content
Based in Cambridge, Mass., the biotech specializes in the development and delivery of treatments for neurological diseases. Biogen has developed medications for multiple sclerosis, plaque psoriasis, spinal muscular atrophy, and leukemia, and has research programs focused on neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, and neuropathic pain.
John Tlumacki—The Boston Globe/Getty Images
Lists ranking Biogen
Fortune 500 - 2021This year’s Fortune 500 marks the 67th running of ...READ MOREview in list